| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C04B35-632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D257-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D257-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate |
2004-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab044169550a11daa43810d44d73d92d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3bdc4001b792a05d0c77e70e59b1158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad35a61830bf18bb700e075f84c92734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5336cac85415786e1752e84ce17a05aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15f1242ae7146b6badc9bc6c9008134d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_957516a9f8920a9b9825caa3d58c140a |
| publicationDate |
2009-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-546257-A |
| titleOfInvention |
P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same |
| abstract |
The disclosure relates to an effective p-glycoprotein inhibitor compound of formula (I) and a pharmaceutically acceptable salt thereof, a method for preparing the same and a pharmaceutical composition containing the same as an active ingredient. The bioavailability of an anticancer agent is enhanced when the anticancer agent is administered together with a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof by suppressing p-glycoprotein. |
| priorityDate |
2003-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |